Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
May 31, 2002
Primary Completion Date
February 28, 2006
Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG
imatinib mesylate
Trial Locations (2)
20892-1182
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda
20892-1906
NCI - Center for Cancer Research, Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00039585 - Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | Biotech Hunter | Biotech Hunter